**Barry H. Greenberg, MD, FACC**
**Distinguished Professor of Medicine; Director, Advanced Heart Failure Treatment Program**
UC San Diego Medical Center

**Printed as of 11/18/2026**

# Disclosures

## Personal Commercial (25)

| Company Name | Relationship Category | Compensation Level | *Topic Area(s)* |
|---|---|---|---|
| ***Self*** | | | |
| ACI | Other - *Critical Events Committee* | Significant (>= $5,000) | *Other* |
| Affinia | Consultant Fees/Honoraria | Modest (< $5,000) | *Heart Failure and Cardiomyopathies* |
| Akero | Data Safety Monitoring Board | Modest (< $5,000) | *Acute Coronary Syndromes* |
| AstraZeneca Pharmaceuticals | Consultant Fees/Honoraria | Modest (< $5,000) | *Heart Failure and Cardiomyopathies* |
| BoerhingerIngelheim | Data Safety Monitoring Board | Modest (< $5,000) | *Heart Failure and Cardiomyopathies* |
| Bristol-Myers Squibb Company | Consultant Fees/Honoraria | Modest (< $5,000) | *Heart Failure and Cardiomyopathies* |
| Colcott | Data Safety Monitoring Board | Modest (< $5,000) | *General Cardiology* |
| Corvia | Data Safety Monitoring Board | Modest (< $5,000) | *Heart Failure and Cardiomyopathies* |
| EBR Systems | Data Safety Monitoring Board | Modest (< $5,000) | *Heart Failure and Cardiomyopathies* |
| Edgewise | Data Safety Monitoring Board | Modest (< $5,000) | *Heart Failure and Cardiomyopathies* |
| Edwards Laboratories | Data Safety Monitoring Board | Modest (< $5,000) | *Heart Failure and Cardiomyopathies* |
| Farady | Data Safety Monitoring Board | Modest (< $5,000) | *Heart Failure and Cardiomyopathies* |
| Impulse Dynamics | Data Safety Monitoring Board | Modest (< $5,000) | *Heart Failure and Cardiomyopathies* |
| Intellia | Data Safety Monitoring Board | Modest (< $5,000) | *Heart Failure and Cardiomyopathies* |
| Inventiva | Data Safety Monitoring Board | Modest (< $5,000) | *Other* |
| Ionis | Data Safety Monitoring Board | Modest (< $5,000) | *Heart Failure and Cardiomyopathies* |
| Ionis | Consultant Fees/Honoraria | Modest (< $5,000) | *Heart Failure and Cardiomyopathies* |
| Ionis | Data Safety Monitoring Board | Modest (< $5,000) | *Heart Failure and Cardiomyopathies* |
| Momentum | Data Safety Monitoring Board | Modest (< $5,000) | *Heart Failure and Cardiomyopathies* |
| Pfizer | Data Safety Monitoring Board | Modest (< $5,000) | *Heart Failure and Cardiomyopathies* |
| Rocket | Research/Research Grants<br>*‡ Gene therapy trials for patients with Danon disease, PKP2 ACM and BAG3 DCM* | Significant (>= $5,000) | *Heart Failure and Cardiomyopathies* |
| Rocket Pharma | Consultant Fees/Honoraria | Modest (< $5,000) | *Heart Failure and Cardiomyopathies* |
| Tenax | Data Safety Monitoring Board | Modest (< $5,000) | *Heart Failure and Cardiomyopathies* |
| Tenaya | Consultant Fees/Honoraria | Modest (< $5,000) | *Heart Failure and Cardiomyopathies* |
| Tenaya | Consultant Fees/Honoraria | Modest (< $5,000) | *Heart Failure and Cardiomyopathies* |

## Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

## Personal Organizational or Other Non-Commercial (0)

No disclosures on record

## Clinical Trial Enroller (0)

No disclosures on record

## Institutional Financial Decision-Making Role (0)

No disclosures on record

## Expert Witness Testimony (0)

No disclosures on record

*† Commercial Funding Source | ‡ Trial Name*

# Agreement

### Certified Education Attestation | Signed on 8/11/2026

*URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement*

### Confidentiality, Disclosure and Assignment Agreement | Signed on 8/11/2026

*URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement*

### Embargo | Signed on 8/11/2026

*URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement*

### On-Going Obligation Agreement | Signed on 8/11/2026

## ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.